Oncocross (A382150) Stock Overview
Develops drugs for the treatment of cancers, rare diseases, and intractable diseases in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
A382150 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Oncocross Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩6,960.00 |
| 52 Week High | ₩16,700.00 |
| 52 Week Low | ₩6,150.00 |
| Beta | 0 |
| 1 Month Change | -12.56% |
| 3 Month Change | -30.47% |
| 1 Year Change | -39.48% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -22.32% |
Recent News & Updates
Shareholder Returns
| A382150 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -0.6% | 1.8% | 5.4% |
| 1Y | -39.5% | 35.8% | 117.3% |
Return vs Industry: A382150 underperformed the KR Biotechs industry which returned 31.6% over the past year.
Return vs Market: A382150 underperformed the KR Market which returned 108.1% over the past year.
Price Volatility
| A382150 volatility | |
|---|---|
| A382150 Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in KR Market | 15.4% |
| 10% least volatile stocks in KR Market | 4.2% |
Stable Share Price: A382150 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A382150's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 31 | Yi Rang Kim | www.oncocross.com |
Oncocross Co., Ltd. develops drugs for the treatment of cancers, rare diseases, and intractable diseases in South Korea. Its products pipeline includes OC101 for liver cirrhosis; OC101+OC111 for non-alcoholic steatohepatitis; OC201+OC202e for Inhibition of cancer metastasis; OC211, a Pan-KRAS Inhibitor; OC221, an immuno-oncology combination; OC514 to treat amyotrophic lateral sclerosis and Duchenne muscular dystrophy; and OC701 to treat atopic dermatitis. The company is also developing OJP3101 for metabolic disease; OJP3101 for Cardiovascular Disease; ODP9401 for metabolic disease; and ODP2201, ODP2301, and ODP2401 to treat oncology-related diseases.
Oncocross Co., Ltd. Fundamentals Summary
| A382150 fundamental statistics | |
|---|---|
| Market cap | ₩84.88b |
| Earnings (TTM) | -₩8.33b |
| Revenue (TTM) | ₩884.68m |
Is A382150 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A382150 income statement (TTM) | |
|---|---|
| Revenue | ₩884.68m |
| Cost of Revenue | ₩227.45m |
| Gross Profit | ₩657.23m |
| Other Expenses | ₩8.99b |
| Earnings | -₩8.33b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -683.42 |
| Gross Margin | 74.29% |
| Net Profit Margin | -942.14% |
| Debt/Equity Ratio | 29.7% |
How did A382150 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/18 00:35 |
| End of Day Share Price | 2026/03/18 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oncocross Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.